BioCentury
ARTICLE | Company News

Avillion, Merck KGaA deal

April 7, 2017 4:22 AM UTC

The companies partnered to develop Merck’s M1095 (ALX-0761) to treat plaque psoriasis. Avillion will be responsible for developing the candidate through Phase III testing and will also finance development through to a regulatory submission. Phase II testing is slated to start this year. The partners declined to disclose financial terms...

BCIQ Company Profiles

Avillion LLP

Merck KGaA

BCIQ Target Profiles

IL-17A

IL-17F